CBUS
NASDAQ
US
Cibus, Inc. - Class A Common Stock
$1,98
▲ +$0,05
(+2,59%)
Vol. 375K
4
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$94.5M
ROE
-166,9%
Margine
-3133,9%
D/E
1,54
Beta
1,93
52W
$1–$3
Consenso Wall Street
9 analisti · Apr 20262
Acquisto forte
5
Compra
2
Mantieni
0
Vendi
0
Vendita forte
77,8%
Rating Compra
Grafico dei Prezzi
Titoli simili
DTIL
Precision BioSciences Inc
$100.1M
FATE
Fate Therapeutics Inc
$113.3M
SPRO
Spero Therapeutics Inc
$131.3M
BDTX
Black Diamond Therapeutics Inc
P/E 6,4
$138.4M
KLRS
Kalaris Therapeutics Inc
$141.3M
AGEN
Agenus Inc
$106.8M
EQ
Equillium Inc
$94.4M
HUMA
Humacyte Inc
$185.4M
IMDX
Insight Molecular Diagnostics Inc
$215.0M
Utili
Tasso di battuta: 40,0%
Prossimo report
Mag 06, 2026
Stima EPS: $-0,34
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,34 | — | — |
| Dic 2025 | $-0,44 | $-0,59 | $-0,15 |
| Set 2025 | $-0,53 | $-0,44 | +$0,09 |
| Giu 2025 | $-0,71 | $-0,61 | +$0,10 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | $1.7M | $1.2M | $1.0M | $933K | $615K |
| Utile netto | -$180.0M | -$23.1M | -$46.9M | -$25.4M | -$23.5M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -321.5% | -203.5% | -321.4% | -321.4% | -321.5% | -166.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -2719.4% | -5787.3% | -5681.6% | -5681.6% | -5682.2% | -3133.9% |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| D/E Ratio | 1.70 | 0.90 | 1.70 | 1.70 | 1.70 | 1.54 |
| Current Ratio | 1.78 | 1.23 | 1.78 | 1.78 | 1.78 | 1.28 |
Rapporti chiave
ROA (TTM)
-34,9%
P/S (TTM)
24,90
P/B
0,9
EPS (TTM)
$-3,26
CF/Share
$-9,69
Crescita ricavi 3A
-45,3%
52W High
$3,40
52W Low
$1,09
$1,09
Intervallo 52 settimane
$3,40
Salute finanziaria
Flusso di cassa libero
-$11.8M
Debito netto
$10.1M
Liquidità
$23.9M
Debito totale
$33.9M
Aggiornato al Set 30, 2025
Як CBUS виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CBUS vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
24,9
▲
94%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
0,9
▼
64%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CBUS vs аналоги Biotechnology
ROE
-166,9%
▼
148%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-3133,9%
▼
993%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
100,0%
▲
27%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-34,9%
▲
25%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя CBUS vs аналоги Biotechnology
D/E ratio
1,5
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
In linea
Поточна ліквідність
1,3
▼
71%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
1,9
▲
99%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CBUS
CBUS
Mediana peer
Industria
CBUS прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio